319474-35-6 Usage
Derivative of indazole
Indazole is a heterocyclic aromatic organic compound The compound is based on the indazole structure, which is a five-membered ring with one nitrogen atom and one double bond, making it an aromatic compound.
3-formyl group
Presence of an aldehyde functional group The compound contains a formyl group (-CHO) which is an aldehyde functional group, known for its reactivity and potential for further chemical modification.
Reactivity
Important reactivity due to the presence of the aldehyde group The aldehyde group in the compound allows for various chemical reactions, such as oxidation, reduction, and condensation reactions, which can lead to the formation of new compounds.
Potential applications
Pharmaceutical industry, drug development, and therapeutics 1H-Indazole-6-carboxylic acid, 3-formylhas potential uses in the pharmaceutical industry, particularly in the development of new drugs and therapeutics.
Structure and properties
Of interest for research and development in medicinal chemistry The compound's structure and properties make it a valuable subject for further research and development in the field of medicinal chemistry, as it may lead to the discovery of new drugs and treatments.
Check Digit Verification of cas no
The CAS Registry Mumber 319474-35-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,1,9,4,7 and 4 respectively; the second part has 2 digits, 3 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 319474-35:
(8*3)+(7*1)+(6*9)+(5*4)+(4*7)+(3*4)+(2*3)+(1*5)=156
156 % 10 = 6
So 319474-35-6 is a valid CAS Registry Number.
319474-35-6Relevant articles and documents
Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
-
, (2008/06/13)
Indazole compounds that modulate and/or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction and thereby modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.
